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Managed aquifer recharge system 
A B S T R A C T   
The presence of pharmaceutically active compounds (PhACs) in drinking waters might pose a serious threat to 
human health worldwide. Therefore, this study sought to measure PhACs in Danube-derived tap water from the 
Budapest metropolitan region (Hungary), and to compare the results of those measured in the bank filtrate after 
which a human health risk assessment (based on human risk quotient [hRQ]) was conducted for the detected 
PhACs. A total of 108 samples were collected from 21 sampling sites throughout 6 sampling campaigns. Our 
study screened for 102 PhACs, of which 19 were detected in the persistently chlorinated tap water samples. PhAC 
concentrations were much lower than previously assumed based on the contamination of raw water resources. 
The total mean concentration of the analyzed PhACs exceeded 30 ng L− 1 only at 5 sites. Moreover, the frequency 
of occurrence (FRO) of the 6 most common compounds (carbamazepine, lamotrigine, lidocaine, benzoylecgo-
nine, tramadol, and cinolazepam) reached 50 % at 4 sites. The most frequent PhAC was carbamazepine (FRO =
53.7 %), the risk level of all PhACs investigated was negligible (hRQ<1) with carbamazepine having the highest 
hRQs (hRQMAX = 0.007; hRQMEAN = 0.001). Tap water provided lower PhAC concentrations farther from the 
water abstraction wells and treatment stations along the Danube. The travel time between the drinking water 
wells and taps with other factors, such as the varying microbiological pattern and the deposits in the supply 
system influence the PhAC concentrations. Based on the risk assessment, all investigated PhACs pose a negligible 
risk to consumers in the investigated urban area.   
1. Introduction 
Due to the increase in human pharmaceutical consumption, several 
pharmaceutically active compounds (PhACs) are released into the 
environment each day [1–3]. The main source of these organic micro-
pollutants is untreated and treated wastewater, as common wastewater 
treatment processes are incapable of removing all pharmaceuticals from 
contaminated water [4–7]. Although PhACs generally occur at low 
concentrations in various environmental matrices (i.e., typically at the 
ng L− 1 or μg L− 1 level), the occurrence and risks of pharmaceuticals with 
their metabolites or conjugates in the environment is a growing 
worldwide concern [8–10]. This problem is exacerbated by the fact that 
adverse neurophysiological or genotoxic effects have been linked to 
certain groups of pharmaceuticals (e.g., antiepileptics, opiates), which 
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may have mutagenic and/or carcinogenic effects [11–14]. Given that 
water resources may also be affected by PhAC contamination [15–18], 
several studies have associated the occurrence of PhACs in raw or 
treated tap water with serious health risks of [19–21] including geno-
toxicity and carcinogenicity [22,23]. Moreover, although some PhACs 
(e.g., hormones, psychoactive substances, anxiolytics, antiepileptics, 
antibiotics) are known to pose significant risks to aquatic organisms 
[24–29], the level of human health risk is generally low or negligible in 
drinking water because they are present only at trace concentrations 
[30–35,102,103]. 
Several regionally varying factors can influence the degree of expo-
sure and risk associated with tap water consumption. The absolute 
amount of PhACs released into the environment is the highest in densely 
populated metropolitan areas [33], but this can be significantly reduced 
by more advanced wastewater treatment technologies [36]. Given 
wastewater treatment plants (WWTPs) are a significant source of 
emerging environmental contaminants, PhAC concentrations in raw 
water are fundamentally determined by the efficiency of wastewater 
treatment procedures [10]. Generally, the fate of the pharmaceuticals 
depends on their degree of natural attenuation and their physicochem-
ical properties, such as their hydrophobicity index (log P, log kW), sol-
ubility in water, and chemical structure [37]. It is important to note that 
these properties are seriously affected by the local factors or 
micro-environmental parameters (e.g. hydrolysis, photolysis, microbial 
degradation or biodegradation [38,39]. Geological and hydrological 
characteristics of drinking water sources are very different; however, 
polluted rivers, lakes, or shallow groundwater are the main sources of 
drinking water in many countries [40]. Drinking water treatment 
methods and their efficacy also vary widely, which also affects PhAC 
concentrations [35]. Although the most commonly consumed PhAC 
(and associated substances) entering the waterways may vary from 
country to country, many pollutants are ubiquitous and their potential 
interactions may increase the risks associated with tap water con-
sumption. Moreover, the level of contamination in drinking water and 
the vulnerability of certain groups of people are not constant. In China, 
for example, pollution trends are clearly on the rise according to several 
comparable studies [36]. Furthermore, different age groups and de-
mographics (e.g., children, pregnant women, elderly people) may be 
more sensitive to even relatively low PhAC concentrations [16]. Given 
that safe drinking water is not only a fundamental determinant of 
quality of life but also a basic human necessity [41], tap water pollution 
monitoring and risk assessment should be conducted regularly [17,42]. 
Riverbank filtration (RBF) plays a fundamental role in drinking 
water supplies along rivers and pounds worldwide. Although aquifers 
close to the river are highly exposed to anthropogenic stress, many 
pollutants are efficiently removed by the managed aquifer recharge 
(MAR) system, which reduces the necessity of conventional drinking 
water treatment [43–45]; however, lower natural removal is observed 
for some emerging organic micropollutants such as persistent PhACs. In 
Hungary, the daily water requirements of 40 % of the population 
(approximately 4 million people) are covered by riverbank filtered 
water (RFW) [101]. Furthermore, RFW is also very important in 
neighboring countries along the river Danube (e.g., Slovakia, Serbia) 
[46]. Due to the high efficiency of RBF, drinking water is only routinely 
chlorinated for disinfection and, with a few exceptions, no multi-stage 
drinking water treatment systems are in operation therefore, persistent 
micropollutants such as certain PhACs can infiltrate into potable water 
sources and reach the drinking water supply system [43,47–49]. 
In our previous study, the efficiency of riverbank filtration was 
examined and quantified in the Budapest metropolitan region [43,50]. 
To explore the connection between surface water and drinking water we 
scanned the same PhACs in the present study. However, PhAC concen-
trations have not yet been determined in the chlorinated tap water. 
Therefore, this study evaluated PhAC concentrations in river bank fil-
trated tap water, their potential seasonal changes, and their associated 
human health risk assessment (HHRA) in the Budapest metropolitan 
region. Specifically, we hypothesized that i) the same PhACs are present 
at the same concentrations in tap water as they are found in raw drinking 
water indicating the incomplete effect of chlorination on persistent 
PhAC concentrations decrease; ii) PhAC concentrations in tap water 
vary in time and space reflecting the role of raw water characteristics 
and the supply system; iii) PhACs in tap water pose low health risks. 
2. Materials and methods 
2.1. Study area 
Water samples were obtained from the Budapest metropolitan re-
gion, which is a highly urbanized area in Hungary with nearly 3 million 
inhabitants (Fig. 1). RFW accounts for more than 90 % of the water 
supply, and the rest of the drinking water is provided by artesian wells 
and karst water springs. In this region, more than 1000 drinking water 
abstraction wells are operated by two large waterworks (Budapest 
Waterworks and Danube Regional Waterworks), in addition to some 
smaller suppliers. Budapest Waterworks alone operates approximately 
750 wells to supply 1.89 million inhabitants, and the majority of the 
drinking abstraction wells operate along the riverbank of the Danube 
[51]. 
Due to the predominantly oxidative conditions of the RBF, chlori-
nation with chlorine gas and hypochlorite is the most important primary 
water treatment method [52]. As a first step, prechlorination occurs 
along the collecting system to achieve a target free chlorine level. For 
further disinfection, chlorine gas and hypochlorite are also applied in 
drinking water treatment plants, which are located close to the Danube. 
Fig. 1. Sampling area in the Budapest Metropolitan Region, Hungary. Location 
of the study site within Europe (A); sampling sites in the region (B). 
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Secondly, supplied drinking water quality is continuously monitored 
along the entire collector and supply system to ensure uninterrupted safe 
water quality for consumers. One important performance indicator is to 
maintain a constant free chlorine level of 0.3 mg L− 1 in the entire supply 
system. Chlorination or hypochlorite solution dosing occurs along the 
supply system based on online measurements to ensure the required 
water quality standards at the consumer’s tap. 
Although river regulations and organic matter loads have resulted in 
riverbed siltation in some locations, which might lead to anoxic condi-
tions due to iron and manganese dissolution [51], the removal of iron 
and manganese is of lesser importance, only 20–25 % of the total raw 
water is purified with advanced treatment processes (ozonation, floc-
culation, and granulated active carbon (GAC) filtration). 
Sampling sites Nr. 1 and 2 (Fig. 1) were two local drinking water 
supply system taps. In these sites, the water of the Danube and the wells 
were not affected by the large WWTP effluents of Budapest. For the 
majority of the sampling sites, the extracted water was mixed by col-
lector wells and large pumping stations, after which a complex, more 
than 8000 km long pipe network supplies the water to the consumers. 
Therefore, neither the exact origin and associated drinking water well of 
a particular tap water sample nor the travel time of the water in the 
complex supply system could be appropriately determined. The supply 
system is made of pipes of different materials (asbestos cement: 43 %; 
cast iron, ductile iron, steel: 32 %, PVC and polyethylene: 23 %; rein-
forced concrete pipe: 2%). The older sections of the drinking water 
supply system are not in good technical condition, the water loss rate is 
significant, around 20 %. In 2015 and 2018, a partial pipe cleaning 
program has been implemented concerning the iron pipes at the Buda-
pest Waterworks because the water flow has reportedly decreased due to 
deposits: 50 % of the deposits removed were siderite, 25 % goethite and 
green rust, while the proportion of calcite and magnetite was only a few 
percent [95]. 
Although the water is distributed via complex supply systems, and 
therefore there is no exact data on the water residency time in the 
pipeline, the water distribution models for the waterworks concerned 
show that the chlorinated drinking water stays in the network for an 
average of 1–3 days. Nevertheless, the travel time next to the Danube (i. 
e., close to the drinking water wells) is shorter than in the eastern and 
southern sampling points. The sampling points next to the Danube (Nr. 
1–15) are closer to the drinking water abstraction wells and therefore 
the water flows more rapidly. In contrast, the tap water in the eastern 
and southern parts of Budapest take longer to flow through the pipeline 
because it is further away from the water sources and pumping stations. 
To compare the results, the tap water from an artesian aquifer (sampling 
site 21) located far from the Danube and presumed to be completely free 
of PhACs was also sampled. 
2.2. Experimental design and procedures 
A total of 108 tap water samples were collected from 21 sampling 
sites (e.g., public places, the ground floor of shops, consulting rooms, 
pharmacies, schools, and nursery schools) throughout six sampling pe-
riods from November 2017 to November 2018. To elucidate seasonal 
differences, three sampling campaigns were conducted in the winter 
period (66 samples in October–March), followed by three more cam-
paigns in the summer period (42 samples in April–September). 
The samples were taken from the taps as grab samples using 
disposable nitrile latex gloves. At the beginning of the sampling process, 
tap water was allowed to flow for 5 min. The sampled taps were not 
equipped with any special filters or water purifier devices. Before sam-
pling, all sampling glass bottles were rinsed 3 times with the sampled 
water. Unused 500 mL amber borosilicate glass bottles with a poly-
propylene screw cap (VWR International, Pennsylvania, USA) were used 
for general water chemistry analyses. To measure the total organic 
carbon and total nitrogen contents, a 50 mL sample was taken directly 
from the water into transparent borosilicate glass bottles (VWR 
International, Pennsylvania, USA), to which 500 μL of 2 M hydrochloric 
acid (VWR International, Pennsylvania, USA) was added. To measure 
PhACs, 2.5 L of water was collected in amber borosilicate glass bottles 
with Teflon-faced caps (Thermo Fisher Scientific, Massachusetts USA) as 
grab samples from the running water, after which each sample was 
acidified by applying HPLC-grade cc. formic acid (VWR International, 
Pennsylvania, USA) to pH 3.5–4.0. 
For elemental analyses, glass jugs were first rinsed 3 times with 
running water, then filled with tap water. A 15 mL tap water sample was 
directly taken from this glass container with a disposable 3-part plastic 
syringe (Van Oostveen Medical B.V. – Romed Holland, Netherlands) and 
transferred into metal-free polypropylene centrifuge tubes with HDPE 
cups (Wuxi NEST Biotechnology Co., Jiangsu, China) through a 0.45 μm 
PTFE syringe filter (Nantong Filterbio Membrane, Nantong City, Jiangsu 
P.R China). Afterward, 100 μL of high-purity cc. nitric acid (VWR In-
ternational, Pennsylvania, USA) was added to the sample. The collected 
samples were cooled in closed boxes for less than 4 h until they arrived 
in the laboratory. 
2.3. Determination of general water chemistry properties 
Electric conductivity and pH were measured with a portable Ponsel 
Odeon-type logger using a combined digital ORP electrode and digital 
EC electrode. Turbidity was measured directly from the water in a glass 
beaker with a turbidimeter (VWR International, Pennsylvania, USA) and 
a portable laboratory multimeter (Hanna Multi Meter, Hanna In-
struments, USA). Anion (fluoride, chloride, sulfate, bromide, and ni-
trate) and cation (ammonium, calcium, magnesium, sodium, and 
potassium) concentrations were determined using a Dionex ICS 5000+
dual-channel ion chromatograph system (Thermo Fischer Scientific, 
Massachusetts, USA). Titrimetric and spectrophotometric methods were 
applied to measure total hardness, alkalinity, phosphate, and nitrite 
concentrations. The total organic carbon and nitrogen concentrations 
were measured with a Multi N/C 3100 carbon/nitrogen analyzer 
(Analytik Jena, Germany). Trace element concentrations (cadmium, 
mercury, lead, chromium, nickel, zinc, and arsenic) were determined 
using an inductively coupled plasma mass spectrometer (PlasmaQuant 
MS Elite, Analytik Jena, Germany). 
2.4. Measurement of PhACs 
PhAC quantitative analysis was conducted via supercritical fluid 
chromatography coupled with tandem mass spectrometry (SFC-MS/ 
MS). The details of the applied sample preparation processes and 
instrumental analytical approaches with validation parameters of 
measured PhACs and data evaluation have been published in previous 
studies [43,53,54]. The parameters of the method, limit of detection 
(LOD), limit of quantification (LOQ), and validation values are listed in 
Table S1. The average absolute solid-phase extraction recovery (to 5 ng 
L− 1 spiked ultra-high quality water) was 76.5 %. Briefly, after acidifi-
cation and spiking using an internal standard (IS; Citalopram-d6, Car-
bamazepine-d10, E2-13C3, and N-ethyloxazepam), the samples were 
vacuum-filtered through a glass microfiber filter (#516-0345, VWR). 
The analytes were desalted and concentrated using an AutoTrace 280 
automata solid-phase extraction system (Thermo Fischer Scientific, 
Massachusetts, USA) using Strata X-CW cartridges (#8B-S035-FCH, 
Phenomenex). The various analytes were eluted in two steps using 
acetonitrile (ACN) (acidic, neutral, and some amphoteric drug residues) 
and NH4OH/ACN (basic, and some amphoteric drug residues) from the 
cartridges into a 5 mL Eppendorf tube, after which the extracts were 
evaporated to dryness under a constant nitrogen gas stream. Finally, the 
extracts were reconstituted with 300 μL ACN. Pharmaceutical residues 
were then detected and quantified via SFC (ACQUITY UPC2 system, 
Waters) coupled with MS/MS (Xevo TQ-S Triple Quadrupole, Waters). 
During chromatography, the target compounds were separated on an 
ACQUITY UPC2 BEH analytical column (#186007607, Waters) at 45 ◦C. 
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The flow rate of the mobile phase was 1.2 mL min− 1, and the injected 
amount was 2 μL in each case. A Continuous 200 bar back pressure was 
applied to maintain the supercritical state. Electrospray ionization was 
provided by a spray voltage of 3 kV in both positive and negative ion 
modes. MS/MS measurements were conducted in 
multiple-reaction-monitoring mode with a relative closed isolation 
window (0.4 m/z). The data was recorded with the MassLynx software 
(V4.1 SCN950) and ion peak detection and evaluation were conducted 
with the TargetLynx XS software (Waters). The observed ions (in m/z) 
were accepted and quantified if they were within the limits of retention 
time, proper MS1 and MS2 masses, internal standard correction, and 
fragmentation pattern. 
2.5. Risk analysis 
In order to assess the potential risk for human health associated with 
the presence of PhACs in drinking water, the human risk quotient (hRQ) 
methodology was applied. The hRQs are defined as the ratio of an 
exposure concentration and a threshold of adverse effects in tap water. 
The values of hRQs were calculated here for different kinds of PhACs in 









where hRQMAX is the worst-case human risk quotient, hRQMEAN is the 
normal state risk quotient, CMAX is the maximum PhAC concentration in 
tap water, CMEAN is the mean PhAC concentration in tap water, and 
DWEL is the drinking water equivalent level (lifetime exposure con-
centration protective of adverse, non-cancer health effects that assume 
all of the exposure to a contaminant is from drinking water). 
According to Eq. (1), the “worst-case” scenario (hRQMAX) is calcu-
lated by dividing the measured maximum concentration (CMAX [ng L− 1]) 
of the given PhAC by a respective DWEL (ng L− 1). However, if CMEAN is 
used instead of CMAX for risk assessment, the result of Eq. (2) would 
illustrate a “normal state.” This formula was used to determine the hRQ 
for the entire investigated year (hRQMEAN). All concentration data used 
for the calculation of hRQs were above the LOQ. If hRQ < 1, it indicates 
no human health risk. 





where ADI is the acceptable daily intake of individual PhACs [ng∙ 
(kg∙day)− 1]; BW indicates the average body weight of Hungarians 
above 15 years of age (76 kg; [99]); DWI is the daily tap water intake, 
which was accepted as 2 L∙day− 1 over 10 years, but less water con-
sumption was recorded for younger age groups (Table S7) in the Hun-
garian Diet and Nutritional Status Survey [100]; AB represents the 
gastrointestinal absorption rate, which was assumed to be 100 % as the 
maximal value; and FOE is the frequency of exposure, which is pre-
sumably 365 days of the year. ADI represents a dose limit of an indi-
vidual PhAC that should not have any undesirable effects on the health 
of a potentially exposed population, including susceptible 
sub-populations [56]. Here, the most of ADIs were obtained from the 
relevant literature [34,57–60] where the point of departure (POD) was 
based 1) on dosage (lowest oral therapeutic dose [LOTD]), 2) on 
different kind of toxicological data (lowest observed effect level [LOEL]) 
or the absence of these data 3) on occupational exposure limits (OELs) 
and to which several uncertainty factors were applied. When several ADI 
values were found to certain PhAC, the minimum value was accepted for 
calculations [58]. For benzoylecgonine (BZE), cinolazepam (CNL), and 
tiapride (TIP), ADIs were not available in the literature. To determinate 
their ADIs, the proposed drinking water concentration limit (BZE: 0.02 
mg L− 1, [98]) and minimum values of pharmaceutical dosage guidelines 
(CNL: 20 mg day− 1, [97]; TIP: 300 mg day-1 [96]) were applied. How-
ever, the HHRA results of BZE, CNL, and TIP need to be carefully 
interpreted due to the high degree of uncertainty. 
Based on ecological risk assessment method, the mixture risk of 




hRQi (4)  
where MRQ is the mixture risk quotient for human. 
The threshold of MRQ was estimated in the same way as for hRQ; 
Table 1 
Concentrations of all PhACs that exceeded their LOQ value in tap water (FRO: Frequency of occurrence) MIN: measured minimum value, MAX: measured maximum 
value, CMEAN>LOQ: average of the measured values > LOQ, CMEAN: average of the measured values of all samples, SD: standard deviation of the measured values >
LOQ).  
Pharmaceutical classification PhACs FRO LOQ CMIN CMAX CMEAN>LOQ CMEAN SD   
Number (%)  ng L− 1 
alkaloids caffeine 11 10.2 10 11.38 38.41 20.85 2.12 7.65 
antidepressants 
bupropion 8 7.4 0.5 0.59 2.58 0.99 0.07 0.67 
citalopram 2 1.9 0.1 0.24 0.59 0.41 0.01 n.a. 
tiapride (TIP) 1 0.9 0.1 0.54 0.54 0.54 0.01 n.a 
antiepileptics 
carbamazepine (CBZ) 58 53.7 0.1 0.15 77.16 16.49 8.86 18.96 
lamotrigine (LTG) 31 28.7 5.0 5.73 145.25 42.68 12.25 35.38 
anxiolytics 
cinolazepam (CNL) 28 25.9 0.1 0.10 3.88 0.52 0.14 n.a. 
oxazepam 5 4.6 0.1 0.17 1.00 0.39 0.02 0.34 
nordiazepam 1 0.9 0.1 0.10 0.10 0.10 0.00 n.a. 
diazepam 1 0.9 0.1 0.18 0.18 0.18 0.00 n.a. 
temazepam 1 0.9 0.1 0.17 0.17 0.17 0.00 n.a. 
cardiovascular drugs 
verapamil 3 2.8 0.05 0.25 1.96 0.92 0.03 0.92 
perindopril (PER) 2 1.9 0.1 0.14 0.28 0.21 0.00 n.a. 
losartan 5 4.6 0.1 0.15 0.81 0.35 0.02 0.28 
SHM* benzoylecgonine (BZE) 37 34.3 0.1 0.10 9.32 0.59 0.20 1.51 
local anaesthetics lidocaine (LID) 30 27.8 0.1 0.10 1.44 0.36 0.10 0.35 
NSAIDs** diclofenac 1 0.9 0.1 4.20 4.20 4.20 0.04 n.a. 
Opioids, morphine derivatives 
embutramide 1 0.9 0.1 0.10 0.10 0.10 0.00 n.a. 
tramadol (TRA) 31 28.7 0.1 0.11 2.60 0.81 0.23 0.67 
n.a. not applicable. 
* Stimulants, hallucinogens, and their metabolites. 
** Non-steroidal anti-inflammatory drugs. 
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therefore, if MRQ < 1, human health risk is presumably negligible. In 
general, the concentration addition method intends to provide infor-
mation on the joint risk of different compounds. This model expects 
compounds with similar modes of action (MoA) to affect additively ac-
cording to the conception of concentration addition when present as a 
mixture [62]. Assuming similar MoAs to assess the worst-case scenario, 
the value of MRQ can be determined by the summation of hRQs to give a 
theoretical value of mixture risk of PhACs investigated. It should be 
noted that the value of MRQ does not give any further information about 
mixture toxicity, it is intended to present a value that can be relative to 
the limit of 1. 
2.6. Data management and evaluation 
The frequency of occurrence (FRO) was calculated for each PhAC as 
the number of samples with a concentration > LOQ divided by the total 
number of samples (108) and expressed as a percentage. As the Shapiro- 
Wilk test did not indicate a normal distribution for the variables 
measured in this study, the Spearman’s Rho test was applied to measure 
the correlation between the variables with a significance level of 95 %. 
Moreover, the independent samples Mann Whitney U test [63] was 
applied to calculate PhAC seasonal differences and the differences of 
PhAC concentrations between the tap and drinking water well samples. 
All statistical analyses were conducted with IBM SPSS Statistics for 
Windows (version 22, IBM Corp., Armonk, NY, USA). 
3. Results and discussion 
3.1. Measured concentrations in tap water samples 
A total of 102 PhACs were monitored in this study with various 
physical chemical characteristics (Table S2), of which 19 PhACs were 
found to exceed the LOQ in the tap water samples (Table 1). Table S3 
presents the measured chemical values and PhAC concentrations in the 
tap water samples. 
The most frequently detected PhAC was the antiepileptic CBZ, which 
occurred in more than half of the tap water samples (FRO: 54 %). This 
was consistent with other studies that confirmed the presence of 
persistent CBZ in supplied drinking water [64]. Several studies reported 
generally lower CBZ concentrations in tap water than those observed 
herein [58,65,66]. However, much higher values have also been pub-
lished (e.g., Kleywegt et al. [35]: 601 ng L− 1; Stackelberg et al. [18]: 258 
ng L− 1). However, our measured mean was such an extremely low 
concentration (e.g., an individual would have to drink two liters of water 
per day for 80 years to reach a 0.5 mg CBZ intake), which is far below the 
therapeutic dose of 800 mg day− 1 [67]. 
Benzoylecgonine (BZE; i.e., a cocaine metabolite), lamotrigine (LTG; 
i.e., an antiepileptic), tramadol (TRA; i.e., an opioid), lidocaine (LID; i. 
e., a local anesthetic), and cinolazepam (CNL; i.e., an anxiolytic) 
occurred in more than 25 % of the tap water samples. However, only 
LTG exceeded a 10 ng L− 1 mean concentration, which is higher than 
reported previously (8.3–9.5 ng L− 1) by Tröger et al. [66]. LID and TRA 
were present at very low mean concentrations (0.10 and 0.23 ng L− 1). 
Moreover, although the occurrence of BZE in tap water has been re-
ported in other regions [68], CNL had not been previously identified in 
drinking water. The occurrence of other substances was sporadic; only 
caffeine was detected in more than 10 samples, but its mean concen-
tration (2.12 ng L− 1) remained below the values reported previously 
[34,69]. This is probably due to the effectiveness of RBF, as caffeine is 
more likely to occur in surface waters and can therefore be an indicator 
of untreated wastewater [70]. Although the efficiency of drinking water 
treatment may be affected by general water chemical parameters (e.g., 
temperature and pH; [71,72]), the concentrations of the six most com-
mon PhACs did not correlate with the measured water chemistry pa-
rameters and trace element concentrations. The strongest Spearman’s 
correlation value was found between BZE and LTG (r = 0.502**) 
(Table S4). 
In a previous study, Kondor et al. [43] reported the PhAC concen-
trations of drinking water wells related to the same region. The well 
samples were taken just a few days prior to the tap water sampling 
campaigns and aimed to investigate the same 102 PhACs as the present 
study. A total of 32 PhACs were quantified in the wells, of which only 19 
compounds were detected in tap water. Table 2 summarizes the PhAC 
concentrations in the drinking water wells and tap water samples, as 
well as concentration changes. 
The concentrations of the most frequent PhACs (e.g., CBZ, LTG, TRA, 
and LID) generally decreased, in the water supply system, however, the 
reasons were not clearly identified. These persistent PhACs, in particular 
CBZ, LTG, and TRA are resistant to chlorination alone, as it was proven 
by several studies [17,73–78]. Only advanced treatment technologies, 
such as, the ozonation and new GAC filtration [36,66], breakpoint 
chlorination [72], or chlorination at lower pH (ca. 5,5) and higher 
concentrations (>3 mgL− 1; Benotti et al. [79,80]) are able to effectively 
remove the most persistent compounds. As less than 25 % of the total 
Table 2 
PhACs concentration changes from the wells to the taps.   
DWAWs* 
(n = 107) 
Tap water 
(n = 108)    
PhACs CMAX CMEAN CMAX CMEAN Mann-Whitney U Significance δcc**  
ng L− 1 ng L− 1 ng L− 1 ng L− 1   % 
benzoylecgonine (BZE) 1.200 0.057 9.320 0.203 4536 0.002 359 
bupropion 2.385 0.044 2.580 0.073 5452 0.050 165 
caffeine 22.067 1.504 38.410 2.124 3432 0.000 141 
carbamazepine (CBZ) 176.055 44.959 77.160 8.858 457 0.000 20 
cinolazepam (CNL) 1.135 0.105 3.880 0.136 1883 0.000 129 
citalopram 0.580 0.016 0.590 0.008 242 0.000 49 
diazepam 0.248 0.006 0.180 0.002 5133 0.001 26 
diclofenac 1.551 0.017 4.200 0.038 717 0.000 220 
lamotrigine (LTG) 849.185 67.447 145.250 12.251 1276 0.000 18 
lidocaine (LID) 6.098 0.798 1.440 0.101 69 0.000 13 
losartan 0.660 0.012 0.810 0.016 1674 0.000 129 
oxazepam 1.580 0.100 1.000 0.018 1085 0.000 18 
perindopril (PER) 1.110 0.029 0.280 0.004 440 0.000 13 
temazepam 0.223 0.002 0.170 0.002 4415 0.000 64 
tiapride (TIP) 0.518 0.006 0.540 0.005 1853 0.000 86 
tramadol (TRA) 26.720 1.806 2.600 0.232 1050 0.000 13 
verapamil 4.784 0.105 1.960 0.025 5412 0.052 24  
* Drinking water abstraction well [43]. 
** Concentration changes of the mean concentrations. 
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drinking water is treated by advanced technology in the study area, the 
micropollutants’ concentrations might be influenced by the iron-oxide 
deposits and the microbiom of the pipelines [81]. The biofilm in the 
water supply system is reported an important factor of removal, as the 
microbial communities of drinking water can decompose a wide range of 
recalcitrant organic contaminants [82]. They occurrence and the related 
efficiency in decomposition vary significantly in the collecting and 
distributing pipelines from the wells to the consumers in Budapest [52, 
83]. Similarly, the porous deposits of different iron salts, oxides, and 
hydroxy salts such as siderite (FeCO3), goethite (alpha-FeOOH), 
magnetite (Fe3O4), and green rust affect the concentration of PhACs. The 
various iron ions catalyse PhACs oxidation whereas the iron deposits 
and salts may adsorb them [84–87]. 
In contrast, BZE, CNL, and some other sporadic PhACs showed sub-
stantially higher average concentrations in tap water than in raw 
drinking water. This could also have been due to a wide range of reasons 
that are confounded by the mixed water flows in the supply. Local 
accumulation of pharmaceuticals [88], or simply inconsistent positive 
detections of PhACs in the analyzed samples [34] are also reported. 
3.2. Temporal and spatial variability of PhAC concentrations 
According to our observations, CBZ concentrations and FRO were 
independent of the season. Consistent with our findings, CBZ exhibited a 
similar presence in all seasonal periods in other studies [89,90]. In 
contrast, other more persistent PhACs such as LTG, LID, TRA, BZE, and 
CNL [43] were detected more frequently in winter than in summer 
(Table S5), even though only BZE exhibited significantly higher con-
centrations (p = 0.001) in the winter period. This is presumably due to 
the lower winter temperatures, which result in lower biodegradation 
rates [43,91]. However, seasonality can depend on many other factors 
such as the seasonal variations in waste and drinking water treatment 
efficiency [36] and biodegradation during bank filtration [92]. 
Furthermore, the consumption patterns of some PhACs such as antide-
pressants or antipyretics are also known to change seasonally [89,90]. 
Although PhACs were detected at each sampling site and the 
measured data may fluctuate locally over time, some spatial differences 
could still be observed (Figs. 2 and 3). Although the six most frequent 
drugs accounted for the majority of the total PhACs (with a few excep-
tions, over 90 % at each sampling site), their FRO and CMEAN markedly 
changed between sites. The less polluted sites were the northernmost 
taps outside the BMR. The summarized average concentration of PhACs 
Fig. 2. Characteristics of PhAC contamination in 21 sampling sites. All PhACs: sum of the mean concentrations of all PhACs detected (ng L− 1); six most frequent: sum 
of the average concentrations of the six most frequent PhACs (ng L− 1); frequency of occurrence: FRO of the six most frequent PhACs (%.). The sampling site numbers 
refer to the point IDs in Fig. 1. 
Fig. 3. Concentration changes of the most frequently occurred PhACs at the 21 sampling sites (ng L− 1). Sampling site numbers refer to the point IDs in Fig. 1.  
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exceeded 30 ng L− 1 at five sampling sites (Nr. 3, 4, 9, 11, 14), from 
which the FRO of the 6 most frequent drugs exceeded 50 % at four 
sampling sites (Nr. 3, 4, 9, 14). In terms of concentration and occur-
rence, the tap water samples were more polluted at sampling sites Nr. 3, 
4, and 9. The reason for these spatial differences could not be appro-
priately identified because, except sampling points Nr. 1, Nr. 2, and Nr. 
21, all other sampling points supplied water that resulted from the 
mixture of several wells across thousands of km of the water supply 
network. Particularly, sampling sites Nr. 1 and Nr. 2 were two taps of a 
local drinking water supply system that were tested in the northern 
corner of the Budapest metropolitan region. In these sites, the water of 
the Danube and the wells were not contaminated at all by the large 
WWTP effluents of the metropolitan region [43]. Sampling site Nr. 21 
was based on an artesian aquifer; however, similar PhAC profiles and 
concentrations were observed between this site and tap water samples 
from riverbank filtrates. In the other cases, the variations in PhAC 
pollution may be related to the distance and travel time from the wells 
and pump stations, which are also the major sites of chlorination. 
Although the degradation efficiency of chlorination may be 
time-dependent for several PhACs [72,93], it has not been proven for 
persistent compounds. Therefore, the chlorination contact times within 
the pipe system alone may not explain the lower values in the southern 
region of the study area and especially in the eastern sampling points, 
which are farther from water wells. 
3.3. Health risk assessment 
Table 3 summarizes the ADIs, PODs, DWELs, hRQMAXs, hRQMEANs, 
and risk evaluation of the identified PhACs, as well as the adult MRQ 
values of the PhAC mixture in tap water. From the 19 detected PhACs, 
PODs for determination of ADIs were not found for nordiazepam and 
embutramide, and therefore risk assessment could not be performed for 
these compounds. As indicated in Table 3, none of the PhACs examined 
during the entire experimental period (not even in the “worst-case” 
scenario) were linked to any kind of human health risk (hRQMAXs<1 and 
hRQMEANs<1). CBZ exhibited the highest hRQs (hRQMAX = 0.007 and 
hRQMEAN = 0.001); however, even this PhAC was far from posing any 
risk. The MRQ based on hRQMEANs (0.001) shows that the consumption 
of tap water with their average PhAC composition poses negligible risk 
to human health. Furthermore, based on the determined MRQ derived 
from hRQMAX values (0.015), tap water consumption was deemed safe 
even in the worst-case scenario considering the PhAC concentrations 
reported above. The hRQs and MRQs were also calculated and examined 
separately for the two studied seasons. The seasonality of the risks fol-
lowed the PhAC concentrations. Similarly, only seasonal differences 
related to BZE were observed, whereas no seasonal differences between 
Table 3 
Human health risk assessment of the tap water for the adults (ADI: acceptable daily intake, POD: point of departure, DWEL: drinking water equivalent level, hRQ: 
human risk quotient, bw: body weight, MRQ: mixture risk quotient for human).  




ng∙ (kg bw 
day)− 1  
ng∙L− 1     
benzoylecgonine* 
(BZE) 
5.26E+02 Proposed limit in drinking water. 2.00E+04 4.66E- 
04 
1.02E-05 negligible [98] 
bupropion 5.71E+04 Lowest titration dose for depression 2.17E+06 1.19E- 
06 
3.38E-08 negligible [59] 
caffeine 1.50E+05 Toxicity (developmental effects in rats) 5.70E+06 6.74E- 
06 
3.73E-07 negligible [34] 
carbamazepine 
(CBZ) 
2.90E+02 LOTD 1.10E+04 7.00E- 
03 
8.04E-04 negligible [58] 
cinolazepam** 
(CNL) 
2.63E+02 Initial dose for elderly patients and patients with 
hepatic and / or renal impairment 
1.00E+04 3.88E- 
04 
1.36E-05 negligible [97] 
citalopram (CTL) 1.40E+01 OEL 5.32E+02 1.11E- 
03 
1.43E-05 negligible [60] 
diazepam 5.70E+00 LOTD 2.17E+02 8.31E- 
04 
7.76E-06 negligible [60] 
diclofenac 5.00E+02 LOEL 1.90E+04 2.21E- 
04 
2.00E-06 negligible [60] 
lamotrigine (LTG) 1.19E+04 Initial monotherapy dose. 4.52E+05 3.21E- 
04 
2.71E-05 negligible [59] 
lidocaine (LID) 7.10E+02 OEL 2.70E+04 5.34E- 
05 
3.75E-06 negligible [60] 
losartan 3.60E+01 LOTD 1.37E+03 5.92E- 
04 
1.18E-05 negligible [58] 
oxazepam 2.80E+02 LOTD 1.06E+04 9.40E- 
05 
1.71E-06 negligible [60] 
perindopril (PER) 2.90E+00 LOTD 1.10E+02 2.54E- 
03 
3.49E-05 negligible [60] 
temazepam 1.10E+01 LOTD 4.18E+02 4.07E- 
04 
3.80E-06 negligible [60] 
tiapride** (TIP) 3.95E+03 Proposed minimal daily dose 1.50E+05 3.60E- 
06 
3.30E-08 negligible [96] 
tramadol (TRA) 7.10E+03 LOTD 2.70E+05 9.64E- 
06 
8.58E-07 negligible [57] 
verapamil 7.10E+01 OEL 2.70E+03 7.26E- 
04 
9.44E-06 negligible [60] 
MRQ    1.48E- 
02 
9.45E-04 negligible   
* Derived from concentration limit of drinking water, taking into consideration the daily water consumption of 2 L and the bodyweight of 76 kg. 
** Derived from dosage data, assuming a value of 1000 as a safety factor (deviser number) for ADI calculation and a 76 kg bodyweight (the average Hungarian weight 
over 15 years). 
*** Assuming the following: body weight = 76 kg (the average Hungarian weight over 15 years; daily water intake = 2 L∙day− 1; gastrointestinal absorption rate = 1; 
frequency of exposure = 1. 
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led to a homogeneous hRQ throughout the year for each PhAC and the 
MRQ (Table S5). 
Only 7 drugs had mean risk quotients (hRQMEAN) greater than 1 ×
10− 5: CBZ, perindopril (PER), LTG, BZE, citalopram (CTL), CNL, and 
losartan (LOS). Although these compounds may have synergistic effects 
with each other (Table S6), due to their low concentrations, these in-
teractions are unlikely to cause a relevant increase in risks. The detected 
PhACs do not pose risks even to children or infants (Fig. 4; for back-
ground data see Table S7), even though the hRQs were found to be 
inversely related to age. 
Our findings were consistent with those of Leung et al. [94], who 
reported at least one order of magnitude higher hRQs for infants than for 
adults. However, for example, in the case of CBZ, if the detected 
maximum was taken into account for infants, the risk would still be 
negligible (hRQMAX = 0.040). The risks parallel with the concentrations 
are substantially reduced in the water supply system. If the riverbank 
filtrate was fed directly into the taps [43,50], the risks associated with 
CBZ, PER, LTG, TRA, and LID exposure would increase 5–8 times due to 
higher concentrations, even though these values would also be negli-
gible from a health risk assessment perspective (Table S8). 
4. Conclusions 
Although surface water is efficiently filtered by the RBF and the 
majority of pollutants are removed, some PhACs can reach the supply 
system and reach the consumer’s tap. Nonetheless, our hypotheses were 
only partially confirmed: 19 of the 102 screened PhACs were detected in 
tap water, meaning that fewer compounds were identified at the con-
sumer’s tap than in the river bank filtrate (32), the concentrations were 
lower than anticipated. Negligible human health risk was identified for 
all compounds. The highest hRQ was determined for CBZ, but it also 
presents a negligible risk to the consumers. However, PhAC concentra-
tions at a given sampling site may fluctuate in a space- and time- 
dependent manner. Contamination can’t be reduced by chlorination 
alone, concentrations are attenuated by other processes, such as varying 
microbial communities of the water supply network, local oxidative/ 
reductive circumstances, which are effective in reducing PhAC con-
centrations and health risk of the detected compounds. However, further 
adequate research is needed to explore the underlying causes of con-
centration changes and the potential toxic byproducts. To explore the 
underlying causes of concentration changes further adequate research is 
needed focusing on the synergic effects of iron deposits and water 
treatments. Given that several PhACs can occur in drinking water based 
on shallow riverbank filtered water sources, it may be necessary to 
continue and extend monitoring to other hazardous substances (e.g., 
toxic byproducts, antibiotics, hormones, and veterinary pharmaceuti-
cals) to understand the cause of their concentration changes in the 
supply network system and to assess their potential health risks in tap 
water. 
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[14] A.Ş. Zülal, K. Haluk, K.Y. Seval, Ş. Vedat, D. Berrin, Oxcarbazepine-induced 
cytotoxicity and genotoxicity in human lymphocyte cultures with or without 
metabolic activation, Toxicol. Mech. Methods 27 (2017) 201–206, https://doi. 
org/10.1080/15376516.2016.1273430. 
Fig. 4. Risk quotient changes with age for the most frequent PhACs and 
the mixture. 
A.C. Kondor et al.                                                                                                                                                                                                                              
Journal of Water Process Engineering 41 (2021) 102039
9
[15] T. aus der Beek, F.A. Weber, A. Bergmann, S. Hickmann, I. Ebert, A. Hein, 
A. Küster, Pharmaceuticals in the environment-Global occurrences and 
perspectives, Environ. Toxicol. Chem. 35 (2016) 823–835, https://doi.org/ 
10.1002/etc.3339. 
[16] O.A. Jones, J.N. Lester, N. Voulvoulis, Pharmaceuticals: a threat to drinking 
water? Trends Biotechnol. 23 (2005) 163–167, https://doi.org/10.1016/j. 
tibtech.2005.02.001. 
[17] S. Mompelat, B. Le Bot, O. Thomas, Occurrence and fate of pharmaceutical 
products and by-products, from resource to drinking water, Environ. Int. 35 
(2009) 803–814, https://doi.org/10.1016/j.envint.2008.10.008. 
[18] P.E. Stackelberg, E.T. Furlong, M.T. Meyer, S.D. Zaugg, A.K. Henderson, D. 
B. Reissman, Persistence of pharmaceutical compounds and other organic 
wastewater contaminants in a conventional drinking-water-treatment plant, Sci. 
Total Environ. 329 (2004) 99–113, https://doi.org/10.1016/j. 
scitotenv.2004.03.015. 
[19] K.A. Baken, R.M.A. Sjerps, M. Schriks, A.P. van Wezel, Toxicological risk 
assessment and prioritization of drinking water relevant contaminants of 
emerging concern, Environ. Int. 118 (2018) 293–303, https://doi.org/10.1016/j. 
envint.2018.05.006. 
[20] C.E.M. dos Santos, A.C. Nardocci, Prioritization of pharmaceuticals in drinking 
water exposure based on toxicity and environmental fate assessment by in silico 
tools: an integrated and transparent ranking, Comput. Toxicol. 9 (2019) 12–21, 
https://doi.org/10.1016/j.comtox.2018.10.005. 
[21] Y. Peng, S. Hall, L. Gautam, Drugs of abuse in drinking water – a review of current 
detection methods, occurrence, elimination and health risks, TrAC – Trends Anal. 
Chem. 85 (2016) 232–240, https://doi.org/10.1016/j.trac.2016.09.011. 
[22] E. Ceretti, M. Moretti, I. Zerbini, M. Villarini, C. Zani, S. Monarca, D. Feretti, 
Occurrence and control of genotoxins in drinking water: a monitoring proposal, 
J. Public Health Res. 5 (2016) 116–121, https://doi.org/10.4081/jphr.2016.769. 
[23] M. Jureczko, J. Kalka, Cytostatic pharmaceuticals as water contaminants, Eur. J. 
Pharmacol. 866 (2020), 172816, https://doi.org/10.1016/j.ejphar.2019.172816. 
[24] Y.J. Lee, S.E. Lee, D.S. Lee, Y.H. Kim, Risk assessment of human antibiotics in 
Korean aquatic environment, Environ. Toxicol. Pharmacol. 26 (2008) 216–221, 
https://doi.org/10.1016/j.etap.2008.03.014. 
[25] Y. Shao, Z. Chen, H. Hollert, S. Zhou, B. Deutschmann, T.B. Seiler, Toxicity of 10 
organic micropollutants and their mixture: implications for aquatic risk 
assessment, Sci. Total Environ. 666 (2019) 1273–1282, https://doi.org/10.1016/ 
j.scitotenv.2019.02.047. 
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carbamazepine and atrazine and screening of suspect organic contaminants in 
surface and drinking waters, Chemosphere 84 (2011) 1085–1094, https://doi. 
org/10.1016/j.chemosphere.2011.04.056. 
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[89] D. Camacho-muñoz, J. Martín, J.L. Santos, I. Aparicio, E. Alonso, Concentration 
evolution of pharmaceutically active compounds in raw urban and industrial 
wastewater, Chemosphere 111 (2014) 70–79, https://doi.org/10.1016/j. 
chemosphere.2014.03.043. 
[90] C.F. Couto, L.C. Lange, M.C.S. Amaral, Occurrence, fate and removal of 
pharmaceutically active compounds (PhACs) in water and wastewater treatment 
plants—a review, J. Water Process Eng. 32 (2019), 100927, https://doi.org/ 
10.1016/j.jwpe.2019.100927. 
[91] M. Varga, J. Dobor, A. Helenkár, L. Jurecska, J. Yao, G. Záray, Investigation of 
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